Eleison obtains EU orphan drug designation for osteosarcoma drug

Eleison Pharmaceuticals received orphan drug designation from the European Commission (EC) for ILC (inhaled lipid-complexed gisplatin), for the treatment of osteosarcoma, a type of bone cancer.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news